Latest News
- Min. Nadda Unveils ?13,000-Crore Bio-Pharma SHAKTI and Chemical Parks Push to Expand India’s Global Chemicals and Biologics Footprint
- Aurobindo Pharma Subsidiary Launches Generic Cancer Drug in US, Expands Oncology Portfolio in Global Generics Market
- KIMS Hospitals Introduces Adaptive Deep Brain Stimulation in India for Advanced Parkinson’s Treatment
Glaxo hides dangers of Zantac for over 40 years
The manufacturer has been aware of this side effect since 1978.
According to Bloomberg, the British pharmaceutical company Glaxo has been concealing the risks of its stomach ulcer and heartburn drug Zantac for more than 40 years.
This was due to the drug's active ingredient ranitidine, which when taken as medicine produces the carcinogen N-nitrosodimethylamine (NDMA), determined the agency. Since 1978, the manufacturer has been aware of this side effect did not recall the drug from pharmacy shelves.
Ranitidine's dangers became widely known in 2019 after which the Drugs were recalled all over the world. Meanwhile, according to a number of pharmacists, the increased risk of cancer from taking Zantac has not been proven.